Regeneron touts one-year diabetic retinopathy data for Eylea

cafead

Administrator
Staff member
  • cafead   Feb 12, 2019 at 12:02: AM
via Regeneron Pharmaceuticals (NSDQ:REGN) touted one-year results from a Phase III trial of its Eylea aflibercept injection in people with moderately severe to severe non-proliferative diabetic retinopathy.

article source
 

<